Julie Reygner

MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

Bastien Laperrousaz, Julie Reygner, Margaux De Seilhac, Antoine Sabourin et autres

MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

Bastien Laperrousaz, Julie Reygner, Margaux De Seilhac, Antoine Sabourin et autres

Abstract 2868: MaaT013 pooled fecal microbiotherapy improves gastrointestinal physiology and controls inflammation which delays GvHD in a proof-of-concept humanized mouse study

Julie Reygner, Margaux De Seilhac, Cyrielle Gasc, Emmanuel Prestat et autres

fr, de, us (code pays fourni par la source)

1150 MaaT034, a new co-cultured microbiome ecosystem therapy candidate, potentiates anti-PD1 mediated antitumoral activity in germ-free mice

Julie Reygner, Charlotte Petitjean, Emmanuel Prestat, Cyrielle Gasc et autres

fr, ca (code pays fourni par la source)

Abstract 2209: MaaT034, a new co-cultured microbiome ecosystem therapy candidate, is capable to safely colonize the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and to stimulate immunity

Bastien Laperrousaz, Julie Reygner, Charlotte Petitjean, Aurore Duquenoy et autres

fr (code pays fourni par la source)

1268 Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing in combination with immune checkpoint inhibitors in solid tumors

Bastien Laperrousaz, Cyrielle Gasc, Julie Reygner, Charlotte Petitjean et autres

fr (code pays fourni par la source)

Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models

Julie Reygner, Johanne Delannoy, Marie-Thérèse Barba-Goudiaby, Cyrielle Gasc et autres

fr, ch (code pays fourni par la source)

Abstract 6687: Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT034) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Bastien Laperrousaz, Julie Reygner, Cyrielle Gasc, Charlotte Petitjean et autres

fr (code pays fourni par la source)

1321 Evaluation of a new co-cultured microbiome ecosystem therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Bastien Laperrousaz, Julie Reygner, Emmanuel Prestat, Cyrielle Gasc et autres

fr (code pays fourni par la source)

Microbiota medicine: towards clinical revolution

Prisca Gebrayel, Carole Nicco, Souhaila Al Khodor, Jarosław Biliński et autres

fr, pl, it, ca, de (code pays fourni par la source)

Effect of daily co-exposure to inulin and chlorpyrifos on selected microbiota endpoints in the SHIME® model

Claire Joly Condette, Narimane Djekkoun, Julie Reygner, Flore Dépeint et autres

fr (code pays fourni par la source)

Freeze-dried fecal samples are biologically active after long-lasting storage and suited to fecal microbiota transplantation in a preclinical murine model ofClostridioides difficileinfection

Julie Reygner, Christine Charrueau, Johanne Delannoy, Camille Mayeur et autres

fr (code pays fourni par la source)